SCHEMBL6157413

SCHEMBL6157413

O=C(O)CC/C(=N\O)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.57
GAA P10253 4/20 0.53
ALDH1A1 P00352 2/20 0.52
CYP2C19 P33261 2/20 0.52
ATM Q13315 1/20 0.51
PPARA Q07869 2/20 0.50
MAPT P10636 2/20 0.49
LMNA P02545 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
HDAC8 Q9BY41 2/20 0.47
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5099030 1.00 NR4A2 (0.57) NR4A2GAAALDH1A1CYP2C19ATM
SCHEMBL5099035 1.00 NR4A2 (0.57) NR4A2GAAALDH1A1CYP2C19ATM
SCHEMBL7962509 0.88 HDAC8 (0.53) NR4A2GAAALDH1A1CYP2C19PPARA
SCHEMBL7962506 0.88 HDAC8 (0.53) NR4A2GAAALDH1A1CYP2C19PPARA
SCHEMBL6923827 0.86 HDAC8 (0.61) NR4A2GAAPPARAMAPTLMNA
SCHEMBL6922818 0.86 HDAC8 (0.61) NR4A2GAAPPARAMAPTLMNA
SCHEMBL6922820 0.86 HDAC8 (0.61) NR4A2GAAPPARAMAPTLMNA
SCHEMBL7834980 0.84 SRD5A2 (0.55) PPARAFFAR1SMN1; SMN2CA12CA1
SCHEMBL6923108 0.84 GAA (0.50) NR4A2GAACYP2C19ATMMAPT
SCHEMBL6929457 0.84 NPC1 (0.57) GAAMAPTMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116640072-A Method for synthesizing oxime compound by catalyzing hydrocarbon bond oxidation through tetradentate nitrogen-containing coordination manganese 陕西师范大学 2023-08-25 CN disclosed
US-20050239854-A1 Body weight gain inhibitors SUGIYAMA YASUO 2005-10-27 US disclosed
US-6924300-B2 Oxyiminoalkanoic acid derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-02 US disclosed
US-6777435-B1 RETINOID-RELATED RECEPTOR FUNCTION REGULATING AGENT TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-08-17 US disclosed
EP-1077957-B1 OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2004-08-04 EP disclosed
EP-1428531-A1 Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-06-16 EP disclosed
US-20030186985-A1 Oxyiminoalkanoic acid derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-10-02 US disclosed
EP-1224178-B1 CRYSTALS OF AN OXYIMINOALKANOIC ACID DERIVATIVE AND THEIR USE AS ANTIDIABETICS TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-06-25 EP disclosed
EP-1304121-A1 BODY WEIGHT GAIN INHIBITORS Takeda Chemical Industries, Ltd. (JP) 2003-04-23 EP disclosed
US-6495581-B1 DRUG FOR TREATING DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE, ARTERIAL SCLEROSIS AND IMPROVING INSULIN RESISTANCE, INFLAMMATORY DISEASE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-12-17 US disclosed
EP-1229026-A1 ALKOXYIMINOALKANOIC ACID DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2002-08-07 EP disclosed
EP-1224178-A1 CRYSTALS OF AN OXYIMINOALKANOIC ACID DERIVATIVE AND THEIR USE AS ANTIDIABETICS Takeda Chemical Industries, Ltd. (JP) 2002-07-24 EP disclosed
US-6251926-B1 OXYIMINOALKANOIC ACID DERIVATIVES HAVING HYPOGLYCEMIC EFFECT AND HYPOLIPIDEMIC EFFECT, IS USEFUL FOR TREATMENT OF DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE INFLAMMATORY DISEASE AND ARTERIOSCLEROSIS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-06-26 US disclosed
WO-2001032637-A1 CRYSTALS OF AN OXYIMINOALKANOIC ACID DERIVATIVE AND THEIR USE AS ANTIDIABETICS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-05-10 WO disclosed
EP-1077957-A1 OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Chemical Industries, Ltd. (JP) 2001-02-28 EP disclosed
WO-1999058510-A1 OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186985-A1 Oxyiminoalkanoic acid derivatives GPR119, IRS1, CPT1A NR4A2 350/4885GAA 2885/4885ALDH1A1 2409/4885
US-20050239854-A1 Body weight gain inhibitors PPARG, GPR119, PPARA NR4A2 158/4885GAA 643/4885ALDH1A1 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.